Clinical Trial Detail

NCT ID NCT02336451
Title A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST